Payment overview · 2025
General Payments
$62.64
2 reported records · 2 companies
Healthcare provider profile · identity verified
Pouya Afshar, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SAN DIEGO, CA · NPI 1184958977
Verified facts
What the public records show
CMS Open Payments records show Pouya Afshar, M.D. received $62.64 in general payments during 2025 across 2 reported records.
Neurocrine BioSciences, Inc. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $31.55 | 50.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.09 | 49.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $62.64 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $31.55 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 89 |
| Eliquis | Apixaban | 383 | 55 |
| Gabapentin | Gabapentin | 369 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 44 |
| Famotidine | Famotidine | 227 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 210 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 30 |
| Mirtazapine | Mirtazapine | 132 | 21 |
| Carvedilol | Carvedilol | 131 | 26 |
| Xarelto | Rivaroxaban | 127 | suppressed |
| Metformin Hcl | Metformin Hcl | 122 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 30 |
| Trazodone Hcl | Trazodone Hcl | 108 | 28 |
| Levetiracetam | Levetiracetam | 105 | 15 |
| Losartan Potassium | Losartan Potassium | 97 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 25 |
| Lansoprazole | Lansoprazole | 80 | 14 |
| Divalproex Sodium | Divalproex Sodium | 78 | 12 |
| Lisinopril | Lisinopril | 78 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 15 |
| Finasteride | Finasteride | 71 | 13 |
| Furosemide | Furosemide | 70 | 25 |
| Donepezil Hcl | Donepezil Hcl | 69 | 12 |
| Baclofen | Baclofen | 68 | 14 |
| Allopurinol | Allopurinol | 66 | 11 |
| Jardiance | Empagliflozin | 66 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 15 |
| Midodrine Hcl | Midodrine Hcl | 62 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 16 |
| Omeprazole | Omeprazole | 61 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 20 |
| Sertraline Hcl | Sertraline Hcl | 58 | 13 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 18 |
| Bumetanide | Bumetanide | 52 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Lactulose | Lactulose | 35 | 17 |
| Alendronate Sodium | Alendronate Sodium | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | suppressed |
| Latanoprost | Latanoprost | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 28 |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Lidocaine | Lidocaine | 31 | suppressed |
| Potassium Chloride | Potassium Chloride | 31 | 15 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Brilinta | Ticagrelor | 30 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Movantik | Naloxegol Oxalate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 12 |
| Droxidopa | Droxidopa | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Neomycin Sulfate | Neomycin Sulfate | 25 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 25 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 18 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 12 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Clozapine | Clozapine | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | suppressed |
| Nystop | Nystatin | 18 | 13 |
| Risperidone | Risperidone | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Zonisamide | Zonisamide | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Demeclocycline Hcl | Demeclocycline Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Travoprost | Travoprost | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62.64 · 2 records | Neurocrine BioSciences, Inc. | INGREZZA, REXULTI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Otsuka America Pharmaceutical, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error